Literature DB >> 25005839

Determinants of false-negative results in non-small-cell lung cancer staging by endobronchial ultrasound-guided needle aspiration.

José Sanz-Santos1, Mireia Serra2, Miguel Gallego3, Concepción Montón4, Borja Cosio5, Jaume Sauleda6, Alberto Fernández-Villar7, Ricardo García-Luján8, Eduardo de Miguel8, Rosa Cordovilla9, Gonzalo Varela9, Enrique Cases10, Felipe Andreo11, Eduard Monsó12.   

Abstract

OBJECTIVES: False-negative results of endobronchial ultrasound-guided transbronchial needle aspiration in non-small-cell lung cancer staging have shown significant variability in previous studies. The aim of this study was to identify procedure- and tumour-related determinants of endobronchial ultrasound-guided transbronchial needle aspiration false-negative results.
METHODS: We conducted a prospective study that included non-small-cell lung cancer patients staged as N0/N1 by endobronchial ultrasound-guided transbronchial needle aspiration and undergoing therapeutic surgery. The frequency of false-negative results in the mediastinum was calculated. Procedure-related, first, and tumour-related, second, determinants of false-negative results in stations reachable and non-reachable by endobronchial ultrasound were determined by multivariate logistic regression.
RESULTS: False-negative endobronchial ultrasound-guided transbronchial needle aspiration results were identified in 23 of 165 enrolled patients (13.9%), mainly in stations reachable by endobronchial ultrasound (17 cases, 10.3%). False-negative results were related to the extensiveness of endobronchial ultrasound sampling: their prevalence was low (2.4%) when sampling of three mediastinal stations was satisfactory, but rose above 10% when this requirement was not fulfilled (P = 0.043). In the multivariate analysis, abnormal mediastinum on computer tomography/positron emission tomography [odds ratio (OR) 7.77, 95% confidence interval (CI) 2.19-27.51, P = 0.001] and extensiveness of satisfactory sampling of mediastinal stations (OR 0.37, 95% CI 0.16-0.89, P = 0.026) were statistically significant risk factors for false-negative results in stations reachable by endobronchial ultrasound. False-negative results in non-reachable nodes were associated with a left-sided location of the tumour (OR 10.11, 95% CI 1.17-87.52, P = 0.036).
CONCLUSIONS: The presence of false-negative ultrasound-guided transbronchial needle aspiration results were observed in nearly 15% of non-small-cell lung cancer patients but in only 3% when satisfactory samples were obtained from three mediastinal stations. False-negative results in stations reachable by endobronchial ultrasound were associated with the extensiveness of sampling, and in stations out of reach of endobronchial ultrasound with left-sided tumours. These results suggest that satisfactory sampling of at least three mediastinal stations by EBUS-TBNA may be a quality criterion to be recommended for EBUS-TBNA staging.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Endobronchial ultrasound-guided transbronchial needle aspiration; False negative; Mediastinum; Non-small-cell lung cancer; Staging

Mesh:

Year:  2014        PMID: 25005839     DOI: 10.1093/ejcts/ezu253

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA.

Authors:  Laura Millares; Mireia Serra; Felipe Andreo; Jose Sanz-Santos; Concepción Montón; Carles Grimau; Miguel Gallego; Laia Setó; Neus Combalia; Mariona Llatjos; Rosa Escoda; Eva Castellà; Eduard Monsó
Journal:  Clin Exp Metastasis       Date:  2015-06-29       Impact factor: 5.150

2.  Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.

Authors:  Maja Guberina; Kaid Darwiche; Hubertus Hautzel; Till Ploenes; Christoph Pöttgen; Nika Guberina; Ken Herrmann; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried Ernst Erich Eberhardt; Martin Schuler; Rüdiger Karpf-Wissel; Martin Stuschke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-05       Impact factor: 9.236

3.  FDG-PET parameters predicting mediastinal malignancy in lung cancer.

Authors:  M Serra Fortuny; M Gallego; Ll Berna; C Montón; L Vigil; M J Masdeu; A Fernández-Villar; M I Botana; R Cordovilla; R García-Luján; E Cases; E Monsó
Journal:  BMC Pulm Med       Date:  2016-12-08       Impact factor: 3.317

4.  Outcomes of patients with non-diagnostic bronchoscopy: A clinico-radiological comparison of patients with diagnostic and non-diagnostic bronchoscopy.

Authors:  Sindhaghatta Venkatram; Damaris Pena; Bharat Bajantri; Gilda Diaz-Fuentes
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Diagnosis and invasive staging: Non-surgical invasive mediastinal staging. Endobronchial ultrasound.

Authors:  Virginia Pajares; Alfons Torrego; Elisabeth Martínnez-Téllez; Juan Carlos Trujillo-Reyes
Journal:  J Clin Transl Res       Date:  2020-09-02

Review 6.  Mediastinal staging for non-small cell lung cancer.

Authors:  Virginia Leiro-Fernández; Alberto Fernández-Villar
Journal:  Transl Lung Cancer Res       Date:  2021-01

7.  Methylation Assessment for the Prediction of Malignancy in Mediastinal Adenopathies Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients with Lung Cancer.

Authors:  Virginia Leiro; Loretta De Chiara; Mar Rodríguez-Girondo; Maribel Botana-Rial; Diana Valverde; Manuel Núñez-Delgado; Alberto Fernández-Villar
Journal:  Cancers (Basel)       Date:  2019-09-20       Impact factor: 6.639

8.  The Value of a Systematic Protocol Using Endobronchial Ultrasound and Endoscopic Ultrasound in Staging of Lung Cancer for Patients with Imaging iN0-N1 Disease.

Authors:  Rosa Cordovilla; Marco López-Zubizarreta; Antonio Velasco; Alberto Álvarez; Marta Rodríguez; Asunción Gómez; Miguel Ángel Hernández-Mezquita; Miguel Iglesias
Journal:  Biomed Hub       Date:  2021-10-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.